Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Slides:



Advertisements
Similar presentations
The Reliable Life Defense. Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume.
Advertisements

Cancer 101 Monica Schlatter, RN, ND, AOCNP. Types of Cancer AIDS- related malignancies AIDS- related malignancies Bone and soft tissue sarcoma Bone and.
Bone Marrow Transplant in Oncology
Laboratory PLANNING - WORKUP Blood Bank Apheresis Immunology Respiratory Dental Cardiology Radiology.
BLOOD TRANSFUSION SUPPORT IN STEM CELL TRANSPLANT
Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
OneMatch Bone Marrow Registry Event February 27, 2010 Woburn Collegiate 2222 Ellesmere Rd (Markham & Ellesmere) 3:30-7:30 pm.
18 and Swabbin: Never Too Young. The Delete Blood Cancer Mission Our mission is our name. We work to “Delete Blood Cancer” by inspiring as many people.
Activity Faculty Luciano J. Costa, MD, PhD Associate Professor of Medicine Department of Medicine and UAB-CCC Bone Marrow Transplantation and Cell Therapy.
Introduction of « TRIMA » in a Regional Blood Transfusion Organisation Dr Bernard LAMY.
Stem cell mobilisation and collection in Glasgow including the use of plerixafor Joy Sinclair Nurse Manager Clinical Apheresis Unit SNBTS, Glasgow.
Thalidomide, Radiation, and Peripheral Stem Cell Transplantation as Combination Treatment for Multiple Myeloma Allison Reczek Department of Biological.
Service d ’ H é matologie On behalf of the « Western Algerian Group of Bone Marrow Transplant » WAG-BMT Haematology and Cell Therapy Depatment Hemobiology.
Hematopoietic stem cell transplantation- HSCT. Principle of HSCT Myeloablation and eradication of residual disease with hogh dose conditioning regimen.
The Impact of Circulation Access in Allogeneic Peripheral Blood Stem Cell Harvest Shang-Hsien Yang1, Tso-Fu Wang2,3, Shu-Hui Wen4, Sung-Chao Chu3, Ruey-Ho.
Transfusion requirements in autologous stem cell transplantation: a single-center-experience Sousse
Radioimmunotherapy as Consolidation in MCL (Mantle Cell Lymphoma) — 8 Years Follow-Up of a Prospective Phase 2 Polish Lymphoma Research Group Study Jurczak.
Liu Baochi Shanghai Public Health Clinical Center affiliated to Fudan University Treating patients with liver cirrhosis by BMT.
Collection of peripheral blood stem cells Dr Kacem Karima Department of clinical haematology -HAO CMH - 26/05/2012.
Bone marrow Transplant in Paediatric Haematology
© 2014 sanofi-aventis U.S. LLC, A SANOFI COMPANY All rights reserved US.PLE Brief Overview of Hematopoietic Cell Transplantation (HCT) Use.
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
White blood cells and their disorders Dr K Hampton Haematologist Royal Hallamshire Hospital.
Platelet Transfusions Indications, dose and administration
March 16Munir Gharaibeh MD, PhD, MHPE1. Hematopoietic Growth Factors Regulate the proliferation and differentiation of hematopoietic progenitor cells.
Tumors of the Bone By: Pretoria Hoyte Etiology: A tumor is a lump or mass of tissue that forms when cells divide uncontrollably. A growing tumor may.
Due to the non-myeloablative nature of the reduced intensity conditioning, following infusion there is a period of mixed-chimerism with both patient and.
Tbo-filgrastim for Neutrophil Count Recovery Following Acute Myeloid Leukemia Induction Therapy and Melphalan Conditioning in Autologous Hematopoietic.
Bone Marrow Transplant
Stem Cell Transplantation
Evaluation of CD19 specific Chimeric Antigen Receptor T cells (CAR19 T-cells) as an optimal bridge to allogeneic transplantation. Phase I trial for patients.
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
An Introduction to Bone Marrow Transplant
Autologous Peripheral Blood Stem Cell Rescue. Multiple Myeloma.
Materials and methods:
Erik Ames, Salif Harouna, Colin Meyer, Lisbeth A. Welniak, William J
Lenograstim Chemical Formula : C840-H1330-N222-O242-S8
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Filgrastim-sndz Drugbank ID : DB09560.
Volume 19, Issue 1, Pages (January 2011)
ASCT for AL Seok Jin Kim
Duration of Therapy of Colony Stimulating Factors in Oncology
Human Health and Disease
A young patient with multiple myeloma
by Qin Huang Blood Volume 122(1):6-6 July 4, 2013
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.
A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing.
Figure 1 Outline of the AHSCT procedure
Peripheral Blood Stem Cell Rescue. Multiple Myeloma.
Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide  Paul Shaughnessy,
Figure 2 Components of each transplantation platform
A Day in the Life of a HCT Financial Coordinator
Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation  Iskra Pusic, Shi Yuan Jiang,
Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing.
High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.
Dendritic Cell Therapies for Hematologic Malignancies
Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.
Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous- BMT Improves the Survival of Leukemia-Challenged Mice  Jenny Zilberberg,
Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma  Mauricette Michallet, Thierry.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant  Ahmad Hatem Mattour,
Bridge to transplant following Bv+Bs regimen.
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.
Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.
Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,
Volume 19, Issue 1, Pages (January 2011)
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management by Elias J. Anaissie, Tahsine.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Autologous Stem Cell Transplantation for POEMS Syndrome
Presentation transcript:

Peripheral Blood Stem Cell Rescue. Multiple Myeloma. Liz Higgins BMT Co-ordinator St James’s Hospital, Dublin

(BMT/ PBSCT) BMT/ PBSCT involves eliminating an individual’s bone marrow stem cells. They are then replaced with bone marrow/ stem cells either from another individual or with a previously harvested portion of the individuals own bone marrow or peripheral blood stem cells.

Reasons for PBSCT To facilitate high dose therapy in some malignant conditions e.G. Lymphoma, testicular cancer, Multiple Myeloma.

Autologous rescue / PBSCT involves two processes. PBSCH/ BMH PBSCT/ BMT

Sources of Bone Marrow Stem Cells Bone marrow (BM) - aspirated from the posterior iliac crests under GA, usually 800-1200mls in volume Peripheral blood stem cells (PBSC) - following the administration of growth colony stimulating factor (G-CSF) + / - chemotherapy

Pathway Referral / Review PBSCH PBSCT Follow up

PBSC Mobilisation Initial Review Bloods Consider venous access – peripheral/centra Medical assessment Nursing Assessment Discussion

PBSC Mobilisation Regimens for MM G-CSF 10mcg/kg x 4 days Cyclophosphamide 2g/m2 + G-CSF 10mcg/kg

Cyclophosphamide 2g/m2 Chemo on Monday Commence G-CSF Tuesday Leucapheresis day 8-10

GSCF ( Neupogen) 10Mcg / kg Round up. Commence on Saturday. CD34 Count Tuesday +/- Gcsf PBSCH

Apheresis 1-3 Days 5-6 Hours Inpatient or Transfer as day patient

Stem Cell Red Cell or White Cell or Platelet Once the ‘decision’ is made it is probably irreversible

COBE

Autologous Stem Cell Rescue Approximately 4-6 weeks post Harvest

Pre Autograft work-up Pulmonary function tests Echocardiogram or MUGA scan Dental Assessment BM Aspirate & Bx Skeletal survey (if applicable) Insertion of PICC or CVC 24 hour urine collection

Conditioning Regimens Melphalan

Denis Burkitt

Shared care National referral centre. Facilitation.